10 results on '"Hiroki Yagi"'
Search Results
2. Giant internal carotid artery aneurysms and porcelain aorta in an elderly patient with Marfan syndrome
- Author
-
Hiroki Yagi, NORIFUMI TAKEDA, Yumiko Hosoya, Haruo Yamauchi, and Issei Komuro
- Subjects
musculoskeletal diseases ,congenital, hereditary, and neonatal diseases and abnormalities ,cardiovascular system ,cardiovascular diseases ,General Medicine ,skin and connective tissue diseases - Abstract
Marfan syndrome (MFS) an inherited disorder caused by FBN1 gene mutations, is well known to cause lethal aortic aneurysm and dissections at a relatively young age. Here, we report giant internal carotid artery aneurysms and porcelain aorta in an elderly patient with MFS.
- Published
- 2022
3. Axitinib Induces and Aggravates Hypertension Regardless of Prior Treatment With Tyrosine Kinase Inhibitors
- Author
-
Hiroshi Akazawa, Yusuke Sato, Junichi Ishida, Issei Komuro, Hiroshi Matsunaga, Hiroki Yagi, Hiroshi Kadowaki, Akiko Saga-Kamo, Ryo Matsuoka, Haruki Kume, Hisataka Maki, Qing Liu, and Masahiko Umei
- Subjects
Oncology ,medicine.medical_specialty ,Axitinib ,medicine.drug_class ,medicine.medical_treatment ,Tyrosine kinase inhibitor ,Tyrosine-kinase inhibitor ,Renal cell carcinoma ,Internal medicine ,medicine ,Hypertension and Circulatory Control ,Chemotherapy ,business.industry ,Original article ,Retrospective cohort study ,General Medicine ,medicine.disease ,Vascular endothelial growth factor receptor ,respiratory tract diseases ,Regimen ,Blood pressure ,Hypertension ,business ,Tyrosine kinase ,medicine.drug - Abstract
Background: Axitinib is a tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptor signaling and is approved for second-line treatment of advanced renal cell carcinoma (RCC). Although the occurrence of hypertension with axitinib use has been documented, it is unclear whether a first-line TKI regimen can significantly affect the development of hypertension when axitinib is used as second-line therapy. Methods and Results: In this single-center retrospective study, advanced RCC patients treated with axitinib after first-line chemotherapy were divided into 2 groups according to the use of TKIs as part of first-line treatment before the initiation of axitinib. Clinical outcomes were compared between patients who were treated with (TKI(+); n=11) or without (TKI(-); n=11) a TKI. Although 63.6% of all patients had hypertension at baseline, axitinib-induced hypertension developed in 81.8% of patients, and 36.4% of patients experienced Grade 3 hypertension. After initiation of axitinib, both systolic and diastolic blood pressures and the hypertension grade were significantly elevated both in the TKI(+) and TKI(-) groups, and the number of antihypertensive drugs was significantly increased among all patients. Conclusions: This study suggests the need for proper monitoring and management of blood pressure in RCC patients treated with axitinib, regardless of a prior regimen with or without TKIs.
- Published
- 2021
4. Family with congenital contractural arachnodactyly due to a novel multiexon deletion of the FBN2 gene
- Author
-
Hiroki Yagi, Hiroshi Takiguchi, Norifumi Takeda, Ryo Inuzuka, Yuki Taniguchi, Kristine Joyce Porto, Hiroyuki Ishiura, Jun Mitsui, Hiroyuki Morita, and Issei Komuro
- Subjects
General Medicine - Published
- 2022
5. Clinical Impact of Copy Number Variation on the Genetic Diagnosis of Syndromic Aortopathies
- Author
-
Ryo Inuzuka, Minoru Ono, Hiroyuki Ishiura, Shoji Tsuji, Yuki Taniguchi, Kristine Joyce L. Porto, Norifumi Takeda, Issei Komuro, Jun Mitsui, Tatsushi Toda, Tsubasa Kanaya, Haruo Yamauchi, Masahiko Ando, Hiroki Yagi, and Hiroyuki Morita
- Subjects
Genetics ,Adult ,Male ,medicine.diagnostic_test ,Adolescent ,DNA Copy Number Variations ,business.industry ,Aortic Diseases ,General Medicine ,Middle Aged ,Precision medicine ,medicine ,Humans ,Female ,Copy-number variation ,Genetic diagnosis ,business ,Child ,Genetic testing - Published
- 2021
6. Impact of Pathogenic FBN1 Variant Types on the Progression of Aortic Disease in Patients With Marfan Syndrome
- Author
-
Hiroyuki Morita, Yoichiro Hirata, Hiroshi Akazawa, Hironori Hara, Hidetoshi Kumagai, Norifumi Takeda, Ryo Inuzuka, Minoru Ono, Sonoko Maemura, Ryozo Nagai, Yasushi Imai, Hiroshi Nishimura, Yuichi Ikeda, Hiroki Yagi, Daishi Fujita, Takayuki Fujiwara, Shinichi Takamoto, Junichi Suzuki, Yuki Taniguchi, Yasunobu Hirata, Haruo Yamauchi, Kan Nawata, Masayoshi Kato, Eisuke Amiya, and Issei Komuro
- Subjects
0301 basic medicine ,Marfan syndrome ,Aorta ,medicine.medical_specialty ,business.industry ,Hazard ratio ,General Medicine ,030204 cardiovascular system & hematology ,medicine.disease ,Gastroenterology ,Confidence interval ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Aneurysm ,medicine.artery ,Internal medicine ,Genotype ,medicine ,In patient ,Haploinsufficiency ,business - Abstract
Background: Marfan syndrome can cause life-threatening aortic complications. We investigated the relationship between FBN1 genotype and severe aortopathy (aortic root replacement, type A dissections, and related death). Methods: We evaluated 248 patients with pathogenic or likely pathogenic FBN1 variants. The variants were classified as haploinsufficient type (HI, n=93) or dominant-negative type (DN, n=155) based on their location and predicted amino acid alterations, and we examined the effects of the FBN1 genotype on severe aortic events (aortic root replacement, type A dissections, and related death). RESULTS: The cumulative event-free probability was significantly lower in the HI group than in the DN group (adjusted hazard ratio, 2.1; 95% confidence interval, 1.4 -3.2; P Conclusions: DN-CD+HI patients should be monitored more carefully than DN-nonCD patients for rapid development of aortic root aneurysms.
- Published
- 2018
7. Congenital Contractural Arachnodactyly without FBN1 or FBN2 Gene Mutations Complicated by Dilated Cardiomyopathy
- Author
-
Issei Komuro, Norifumi Takeda, Norio Kanamori, Koichiro Kinugawa, Takeshi Aoyama, Hiroshi Akazawa, Masafumi Watanabe, Yuki Taniguchi, Yukako Shintani, Saori Harada, Hiroki Yagi, Ichiro Manabe, Hiroyuki Morita, Masaru Hatano, and Yukari Suzuki
- Subjects
Marfan syndrome ,Connective Tissue Disorder ,medicine.medical_specialty ,Pathology ,business.industry ,fungi ,Cardiomyopathy ,Dilated cardiomyopathy ,General Medicine ,Gene mutation ,medicine.disease ,Connective tissue disease ,Camptodactyly ,Internal medicine ,parasitic diseases ,cardiovascular system ,Internal Medicine ,medicine ,Cardiology ,cardiovascular diseases ,medicine.symptom ,Congenital contractural arachnodactyly ,business - Abstract
Congenital contractural arachnodactyly (CCA) is a rare connective tissue disorder characterized by marfanoid habitus with camptodactyly. However, cardiac features have rarely been documented in adults. We herein report a sporadic case of CCA in a 20-year-old woman who developed decompensated dilated cardiomyopathy. The patient did not have any mutations in the FBN1 or FBN2 genes, which are most commonly associated with Marfan syndrome and CCA, respectively. Although whether these two diseases are caused by a mutation(s) in the same gene or two different genes remains unknown, this case provides new clinical insight into the cardiovascular management of CCA.
- Published
- 2015
8. Pathophysiology and Management of Cardiovascular Manifestations in Marfan and Loeys-Dietz Syndromes
- Author
-
Hiroshi Akazawa, Takayuki Fujiwara, Mutsuo Harada, Daishi Fujita, Hironori Hara, Haruhiro Toko, Kan Nawata, Hiroki Yagi, Norifumi Takeda, Issei Komuro, Yuki Taniguchi, and Ryo Inuzuka
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Marfan syndrome ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Angiotensin receptor ,Fibrillin-1 ,Connective tissue ,Bioinformatics ,Loeys–Dietz syndrome ,Losartan ,Marfan Syndrome ,03 medical and health sciences ,Transforming Growth Factor beta ,Internal medicine ,medicine ,Animals ,Humans ,Loeys-Dietz Syndrome ,biology ,business.industry ,Disease Management ,General Medicine ,Transforming growth factor beta ,medicine.disease ,Angiotensin II ,Aortic Aneurysm ,030104 developmental biology ,Endocrinology ,medicine.anatomical_structure ,biology.protein ,Cardiology and Cardiovascular Medicine ,business ,Fibrillin ,Angiotensin II Type 1 Receptor Blockers ,medicine.drug ,Signal Transduction - Abstract
Marfan syndrome (MFS) is an autosomal dominant heritable disorder of connective tissue that affects the cardiovascular, skeletal, ocular, pulmonary, and nervous systems and is usually caused by mutations in the FBN1 gene, which encodes fibrillin-1. MFS is traditionally considered to result from the structural weakness of connective tissue. However, recent investigations on molecular mechanisms indicate that increased transforming growth factor-β (TGF-β) activity plays a crucial role in the pathogenesis of MFS and related disorders, such as Loeys-Dietz syndrome (LDS), which is caused by mutation in TGF-β signaling-related genes. In addition, recent studies show that angiotensin II type 1 receptor (AT1R) signaling enhances cardiovascular pathologies in MFS, and the angiotensin II receptor blocker losartan has the potential to inhibit aortic aneurysm formation. However, the relationship between TGF-β and AT1R signaling pathways remains poorly characterized. In this review, we discuss the recent studies on the molecular mechanisms underlying cardiovascular manifestations of MFS and LDS and the ensuing strategies for management.
- Published
- 2016
9. Inheritance of an Autosomal Recessive Disorder, Gitelman's Syndrome, Across Two Generations in One Family
- Author
-
Koichi Seta, Chinatsu Hasegawa, Hiroki Yagi, Takeshi Usui, Akira Sugawara, and Kensei Yahata
- Subjects
Male ,Heterozygote ,Adolescent ,Receptors, Drug ,Compound heterozygosity ,Genetic analysis ,Hypocalciuria ,Internal Medicine ,Humans ,Medicine ,Solute Carrier Family 12, Member 3 ,Genetic Testing ,Genetic testing ,Genetics ,Symporters ,medicine.diagnostic_test ,business.industry ,Furosemide ,Heterozygote advantage ,General Medicine ,Hypokalemia ,Pedigree ,Mutation ,Mutation (genetic algorithm) ,Female ,medicine.symptom ,business ,Gitelman Syndrome ,medicine.drug - Abstract
Gitelman's syndrome (GS) is an autosomal recessive disorder; it is rarely inherited over several generations. A 16-year-old boy showed hypokalemia and hypocalciuria. Clinically, he was diagnosed as GS because of diuretic responsiveness to furosemide but not thiazide. Genetic testing disclosed he was a compound heterozygote (T180K/V677M) for the SLC12A3 gene. Unexpectedly, the patient's father also showed hypokalemia and hypocalciuria. The genetic analysis showed he had an L849H mutation in addition to T180K. The present pedigree showed an extremely rare case. Diuretic tests are useful diagnostic methods, and genetic testing is necessary for precise evaluation of complicated cases as in this family.
- Published
- 2011
10. In-stent restenosis exacerbated by drug-induced severe eosinophilia after second-generation drug-eluting stent implantation
- Author
-
Masashi Fukayama, Jiro Ando, Hiroki Yagi, Masafumi Watanabe, Issei Komuro, Masako Ikemura, Eisuke Amiya, and Koichi Yanaba
- Subjects
Drug ,Male ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,media_common.quotation_subject ,Biopsy ,Coronary Angiography ,Prosthesis Design ,Severity of Illness Index ,Pathogenesis ,Coronary Restenosis ,Diagnosis, Differential ,chemistry.chemical_compound ,Restenosis ,Internal medicine ,Eosinophilia ,medicine ,Humans ,Coronary Artery Bypass ,media_common ,Aged, 80 and over ,Sirolimus ,business.industry ,Stent ,Drug-Eluting Stents ,General Medicine ,Articles ,equipment and supplies ,medicine.disease ,Coronary Vessels ,Tubulin Modulators ,chemistry ,Drug-eluting stent ,Cardiology ,medicine.symptom ,business ,Immunosuppressive Agents ,medicine.drug ,Follow-Up Studies - Abstract
Patient: Male, 83 Final Diagnosis: In-stent restenosis Symptoms: Chest discomfort Medication: — Clinical Procedure: Cardiac catheterization Specialty: Cardiology Objective: Unusual clinical course Background: In-stent restenosis (ISR) is still a recognized clinical problem in the era of drug-eluting stent (DES). Some previous studies have suggested that circulating eosinophils play an important role in both restenosis and thrombosis after DES implantation. However, the contribution of eosinophils to the pathogenesis of ISR has not yet been concisely clarified. Case Report: We present the case of an 83-year-old male Japanese patient with ISR exacerbated by drug-induced severe eosinophilia. He had previous histories of coronary stent implantations by DES and was referred to our hospital because of erythema with severe eosinophilia (maximum was 6500/μl [48% of total white blood cell count]). Around the same time, the patient developed ISR, for which a stent was deployed 2 years earlier. Arterial wall injury due to the increase in circulating eosinophils was verified in several findings, such as the increase of D-dimer and brain natriuretic peptide. In addition, the histology of the resected tissue from erythema demonstrated that the nuclei of endothelial cells were swollen where eosinophils and lymphocytes heavily infiltrated into the extravascular space, suggesting the presence of vascular injury. This injury due to the increase in circulating eosinophils may have a marked impact on the pathologic process of ISR in DES implantation. Conclusions: Just a few anecdotal reports are available of ISR occurring in the setting of hypereosinophilia. The clarification of the mechanism in this patient provides a new effective therapeutic strategy against ISR in the setting of DES implantation.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.